Trial · NCT00621153
Candesartan Effect in Second Stage Arterial Hypertension
NCT00621153, Phase 4, Completed, AstraZeneca; results first posted 2010-03-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Candesartan Effect in Second Stage Arterial Hypertension. Trials, record NCT00621153. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00621153
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Candesartan Effect in Second Stage Arterial Hypertension
- NCT number
- NCT00621153
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 214 participants, actual
- Lead sponsor
- AstraZeneca
- Conditions
- Stage II Hypertension
- Interventions
- Candesartan Cilexetil, Hydrochlorothiazide, Candesartan Cilexetil
- First posted
- 2008-02-22
- Last updated
- 2010-03-23
- Results first posted
- 2010-03-23
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy | 4 weeks | Mean of the changed DBP from baseline after 4 weeks |
| Secondary | Changes in Mean Sitting SBP From Baseline After 4 Weeks of Therapy | 4 weeks | Mean of the changed SBP from baseline after 4 weeks |
| Secondary | Proportion of Patients Achieving Goal of Mean Trough Sitting DBP (<90 mmHg, But <80 mmHg for DM & Chronic Kidney Disease) and SBP (<140 mmHg, But <130 mmHg for DM & Chronic Kidney Disease) After 4 Weeks of Therapy | 4 weeks | Percent of the patients achieving goal DBP and SBP after 4 weeks |
| Secondary | Proportion of Patients Achieving Goal of Mean Trough Sitting DBP (<90 mmHg, But <80 mmHg for DM & Chronic Kidney Disease) and SBP (<140 mmHg, But <130 mmHg for DM & Chronic Kidney Disease) After 8 Weeks of Therapy | 8 weeks | Percent of patients achieving goal of DBP |
| Secondary | Changes in Mean Sitting SBP From Baseline After 8 Weeks of Therapy | 8 weeks | Changed SBP from baseline after 8 weeks |
| Secondary | Changes in Hs-CRP Level From Baseline After 8 Weeks of Therapy | 8 weeks | Change of hs-CRP from basline after 8 weeks |
| Secondary | Occurrence of Adverse Events (AE) and Discontinuation of Study Medication Due to AE's From Baseline (Randomisation) to the End of the Study (8 Weeks) | 8 weeks | Occurred number of AE and disconinuation of study medication due to the AE from basline after 8 weeks |
| Secondary | Compliance Levels at 4 Weeks and 8 Weeks of Therapy | 8 weeks | Percent of the number of returened pills to the number of prescrited pills |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy | 4 weeks | mmHg | LEAST_SQUARES_MEAN | |
| SECONDARY | Changes in Mean Sitting SBP From Baseline After 4 Weeks of Therapy | 4 weeks | mmHg | LEAST_SQUARES_MEAN | |
| SECONDARY | Proportion of Patients Achieving Goal of Mean Trough Sitting DBP (<90 mmHg, But <80 mmHg for DM & Chronic Kidney Disease) and SBP (<140 mmHg, But <130 mmHg for DM & Chronic Kidney Disease) After 4 Weeks of Therapy | 4 weeks | Participants | NUMBER | |
| SECONDARY | Proportion of Patients Achieving Goal of Mean Trough Sitting DBP (<90 mmHg, But <80 mmHg for DM & Chronic Kidney Disease) and SBP (<140 mmHg, But <130 mmHg for DM & Chronic Kidney Disease) After 8 Weeks of Therapy | 8 weeks | Participants | NUMBER | |
| SECONDARY | Changes in Mean Sitting SBP From Baseline After 8 Weeks of Therapy | 8 weeks | mmHg | LEAST_SQUARES_MEAN | |
| SECONDARY | Changes in Hs-CRP Level From Baseline After 8 Weeks of Therapy | 8 weeks | mg/dl | MEAN | |
| SECONDARY | Occurrence of Adverse Events (AE) and Discontinuation of Study Medication Due to AE's From Baseline (Randomisation) to the End of the Study (8 Weeks) | 8 weeks | Participants | NUMBER | |
| SECONDARY | Compliance Levels at 4 Weeks and 8 Weeks of Therapy | 8 weeks | percent | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy | Candesartan Cilexetil/Hydroclorozide Combination Therapy | -17.0 | Standard Deviation 0.89 | mmHg | |
| Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy | Candesartan Cilexetil Monotherapy | -14.1 | Standard Deviation 0.88 | mmHg |
Source ClinicalTrials.gov
Participant flow8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Candesartan Cilexetil/Hydroclorozide Combination Therapy | 117 | |
| Overall Study | STARTED | Candesartan Cilexetil Monotherapy | 116 | |
| Overall Study | Discontinued | Candesartan Cilexetil/Hydroclorozide Combination Therapy | 20 | |
| Overall Study | Discontinued | Candesartan Cilexetil Monotherapy | 15 | |
| Overall Study | COMPLETED | Candesartan Cilexetil/Hydroclorozide Combination Therapy | 97 | |
| Overall Study | COMPLETED | Candesartan Cilexetil Monotherapy | 101 | |
| Overall Study | NOT COMPLETED | Candesartan Cilexetil/Hydroclorozide Combination Therapy | 20 | |
| Overall Study | NOT COMPLETED | Candesartan Cilexetil Monotherapy | 15 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness | Nervous system disorders | Candesartan Cilexetil/Hydroclorozide Combination Therapy | 6 | 111 | |
| other | Dizziness | Nervous system disorders | Candesartan Cilexetil Monotherapy | 3 | 113 | |
| serious | Breast clacifications | Renal and urinary disorders | Candesartan Cilexetil/Hydroclorozide Combination Therapy | 0 | 111 | |
| serious | Breast clacifications | Renal and urinary disorders | Candesartan Cilexetil Monotherapy | 1 | 113 | |
| serious | Scrub typhus | Skin and subcutaneous tissue disorders | Candesartan Cilexetil/Hydroclorozide Combination Therapy | 0 | 111 | |
| serious | Scrub typhus | Skin and subcutaneous tissue disorders | Candesartan Cilexetil Monotherapy | 1 | 113 | |
| serious | Anal fistula | Gastrointestinal disorders | Candesartan Cilexetil/Hydroclorozide Combination Therapy | 1 | 111 | |
| serious | Anal fistula | Gastrointestinal disorders | Candesartan Cilexetil Monotherapy | 0 | 113 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Candesartan Cilexetil/Hydroclorozide Combination Therapy | ||
| Total, all-cause mortality | Candesartan Cilexetil Monotherapy | ||
| Total, other adverse events | Candesartan Cilexetil/Hydroclorozide Combination Therapy | 6 | |
| Total, other adverse events | Candesartan Cilexetil Monotherapy | 3 | |
| Total, serious adverse events | Candesartan Cilexetil/Hydroclorozide Combination Therapy | 1 | |
| Total, serious adverse events | Candesartan Cilexetil Monotherapy | 2 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 21831438 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00621153
GET https://conductscience.org/api/trials/v1/NCT00621153/registered